Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

TOP - September 2011 Vol 4, No 6

TOP - September 2011 Vol 4, No 6 published on October 1, 2012

What are some treatment options for elderly patients with chronic lymphocytic leukemia?

TOP - September 2011 Vol 4, No 6 published on October 1, 2012

A study by the National Cancer Institute reports that approximately 1 in 5 patients with lung cancer continue to smoke after diagnosis.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in Cancer Center Profile

After the Great Chicago Fire in 1871, Chicago became one of the fastest growing cities in the world. But in this time of prosperity and growth, the prognosis for children born in the city was grim. A child had only a 50% chance of surviving to the age of 5 years, and those who survived were likely to be exposed to a host of diseases. In 1882, Julia Foster Porter took bold steps to transform the future of children’s health in Chicago by renovating a modest home and establishing Chicago’s first—and still its only—hospital dedicated exclusively to caring for children.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in Supportive Care

Significant progress in the treatment of cancer, coupled with early detection, has led to meaningful im - provement in survival and quality of life. Novel symptom and pain-control interventions have made it possible for more patients with cancer to continue to work while receiving chemotherapy and radiation therapy, as well as biologic, hormonal, and targeted agents. In addition, the trend of delivering cancer treatments in the outpatient setting, as opposed to inpatient hospital stays, has reduced time away from work during treatments.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011

Oncology pharmacists have a new tool for helping them better treat their patients. The Association of Community Cancer Centers (ACCC) has released a new publication, “The Practical Cancer Pharmacy,” designed to help hospital cancer pharmacy and financial teams move past the short-term orientation of considering only cost when deciding which drugs to purchase.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in In the News

After neoadjuvant systemic chemotherapy, more BRCA1 carriers achieve a pathologic complete response (pCR) than BRCA2 carriers and than noncarriers, according to a study published online in the Journal of Clinical Oncology (ArunB, et al. September 6, 2011). In addition, the association between gene mutation status and pCR remained, regardless of baseline clinical and tumoral predictive factors or choice of chemotherapy. No statistical difference was found in overall survival rates, however.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in In the News

For patients with non–small-cell lung cancer (NSCLC), concurrent delivery of once-daily chemotherapy and thoracic radiotherapy produced significantly higher 5-year survival in a phase 3 trial (Curran WJ Jr, et al. J Natl Cancer Inst. September 8, 2011. Epub ahead of print).

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in In the News

With the high survival rate of children with acute lymphoblastic leukemia (ALL), there is interest in extending pediatric regimens to adult populations with the disease. Choosing the right therapy for the right patient, however, remains challenging, according to Daniel J. DeAngelo, MD, at the National Comprehensive Cancer Network (NCCN) 6th Annual Congress: Hematologic Malignancies.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in In the News

Lapatinib as adjuvant monotherapy in early HER2-positive breast cancer produced poorer outcomes than trastuzumab in a head-to-head trial, according to the trial’s sponsor. “Consequent to this finding, patients assigned to the lapatinib alone arm of the trial will discontinue lapatinib and discuss treatment options with their study physician,” according to a statement released by GlaxoSmithKline. The 3 other arms of the Adjuvant Lapatinib and/or Trastuzumab Treatment Opt - imization (ALTTO) trial will continue uninterrupted.

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in FDA Approvals

The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris; Seattle Genetics) to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).

With brentuximab, an antibody-drug conjugate, the antibody directs the drug to the target CD30. The agent is to be used in patients with HL whose disease has progressed after autologous stem-cell transplant or, for those who cannot receive a transplant, after 2 lines of chemotherapy. Brentuximab also may be used in patients with ALCL whose disease has progressed after 1 line of chemotherapy.

Page 1 of 2
Results 1 - 10 of 20